(19)
(11) EP 3 200 812 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.04.2021 Bulletin 2021/17

(45) Mention of the grant of the patent:
25.11.2020 Bulletin 2020/48

(21) Application number: 15846131.9

(22) Date of filing: 01.10.2015
(51) International Patent Classification (IPC): 
A61K 38/10(2006.01)
(86) International application number:
PCT/US2015/053558
(87) International publication number:
WO 2016/054411 (07.04.2016 Gazette 2016/14)

(54)

NOVEL ALPHA4BETA7 PEPTIDE MONOMER AND DIMER ANTAGONISTS

NEUARTIGE ALPHA4BETA7-PEPTIDMONOMER- UND -DIMERANTAGONISTEN

NOUVEAUX ANTAGONISTES PEPTIDIQUES MONOMÈRES ET DIMÈRES DE ALPHA4BETA7

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 01.10.2014 US 201462058506 P
01.10.2014 US 201462058510 P
17.04.2015 US 201562149257 P
15.07.2015 US 201562192934 P

(43) Date of publication of application:
09.08.2017 Bulletin 2017/32

(60) Divisional application:
20209378.7

(73) Proprietor: Protagonist Therapeutics, Inc.
Newark, CA 94560-1160 (US)

(72) Inventors:
  • BHANDARI, Ashok
    Pleasanton, California 94588 (US)
  • PATEL, Dinesh V.
    Fremont, California 94539 (US)
  • ZEMEDE, Genet
    San Jose, California 95118 (US)
  • MATTHEAKIS, Larry C.
    Cupertino, California 95014 (US)
  • LIU, David
    Milpitas, California 95035 (US)

(74) Representative: Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB 
Ganghoferstraße 68 B
80339 München
80339 München (DE)


(56) References cited: : 
WO-A1-2014/059213
US-A1- 2006 183 884
 WO-A1-2016/054445
US-A1- 2009 257 952
   
  • GEE ET AL.: 'Cyclic Peptides as Non-carboxyl-terminal Ligands of Syntrophin PDZ Domains' THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 273, no. 34, 21 August 1998, pages 21980 - 21987, XP002155720 DOI: 10.1074/JBC.273.34.21980
  • LIU, S.: 'Radiolabeled Cyclic RGD Peptides as Integrin alphavbeta3-Targeted Radiotracers: Maximizing Binding Affinity via Bivalency' BIOCONJ CHEM. vol. 20, no. 12, 01 December 2010, pages 2199 - 2213, XP055424110 DOI: 10.1021/BC900167C
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).